IL1A and myocarditis: In cases of resistant KD, shock syndrome, worsening coronary artery dilation, or life-threatening myocarditis, anakinra can be added to inhibit interleukin-1 (IL-1) [13, 14] since IL-1 is involved in the pathogenesis of coronary artery aneurysms [15].